SMTL ID : 4cbt.2 (2 other biounits)

Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.03 Å

Oligo State

monomer

Ligands

1 x 9F4: (1R,2R,3R)-2-[4-(5-fluoranylpyrimidin-2-yl)phenyl]-N-oxidanyl-3-phenyl-cyclopropane-1-carboxamide(Non-covalent)

9F4.1: 16 residues within 4Å: Chain A: P.32, E.33, R.37, H.158, H.159, G.167, F.168, D.196, H.198, F.227, D.290, P.298, L.299, G.330, G.331 Ligands: ZN.2 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:P.32, A:E.33, A:F.168, A:F.227 Hydrogen bonds: A:G.167, A:D.196 pi-Stacking: A:F.227

2 x ZN: ZINC ION(Non-covalent)

ZN.2: 4 residues within 4Å: Chain A: D.196, H.198, D.290 Ligands: 9F4.1 4 PLIP interactions: 4 interactions with chain A Metal complexes: A:D.196, A:D.196, A:H.198, A:D.290 ZN.3: 3 residues within 4Å: Chain A: C.23, C.25, H.31 3 PLIP interactions: 3 interactions with chain A Metal complexes: A:C.23, A:C.25, A:H.31

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Burli, R.W. et al., Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. J. Med. Chem. (2013)

Release Date

2013-12-11

Peptides

HISTONE DEACETYLASE 4: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

HISTONE DEACETYLASE 4

Related Entries With Identical Sequence